No one, and I mean no one, understands drug pricing and the policies around regulating them like Stacie Dusetzina, PhD, from the Department of Health Policy at Vanderbilt University School of Medicine, does. So, I was fortunate to have her as my guest on the podcast to discuss the “desensitization” of society to cancer prescription drug costs, the role of advancing science in research and development and drug approvals for rare diseases, the H.R.3 bill in front of Congress, and solutions proposed by politicians for inflated Medicare Part D spending, among other topics.
Everyone is impacted by drug prices; you want to learn more about where we go from here; listening to Dr. Dusetzina is key.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
